User noticed receding temples, used minoxidil and microneedling with positive results. Added saw palmetto and eucapil, experienced shedding and thinner hairline, but no side effects.
The user has tried various hair loss treatments including topical minoxidil, oral finasteride, oral dutasteride, oral minoxidil, and exosome therapy, but none have been effective. They suspect trichodynia might be preventing these treatments from working.
A man used finasteride, minoxidil, and a derma pen for a year to improve hair growth with no significant side effects. He plans to continue the treatment and explore new options.
A user shared progress pictures and discussed their hair loss treatment, including using Hims spray with finasteride, oral finasteride, castor oil, and derma rolling. They reduced their Hims spray dose to every other day to minimize finasteride absorption into the bloodstream.
A 29-year-old male has been taking 1mg finasteride daily for 8 months and using 5% minoxidil with tretinoin but is experiencing increased hair shedding and higher DHT levels. He is concerned about the effectiveness of finasteride and has noticed low libido and occasional ED.
AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.
RU58841 may still be potent after being left unopened for four months if protected from light and air. A user reported hair improvement using RU58841 with minoxidil, without major shedding, over 2.5 years.
The conversation is about selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. The seller offers worldwide shipping.
The user experienced no improvement in hair loss with finasteride and minoxidil but had side effects. They plan to add wounding, scalp massage, vitamin K, and taurine supplements to their regimen and seek feedback on these additions.
The conversation discusses the hair loss treatment Breezula by Cassiopea, which had a successful Phase II trial and is expected to start Phase III by the end of the year. Users are curious about the timeline for availability and note that it performs slightly better than finasteride at 6 months, slightly worse at 12 months, with the benefit of having no side effects.
PP405 shows promising results for hair growth, potentially outperforming finasteride without side effects like erectile dysfunction. Users discuss using treatments like minoxidil, pyrilutamide, nizoral, and alfatradiol while waiting for PP405's availability.
Dutasteride reduces DHT more effectively in hair follicles than finasteride, but some individuals still experience hair loss despite treatment. Combining oral and topical finasteride may improve results, and some users experiment with topical dutasteride despite uncertainties about its absorption.
The user shared a 3-month update on using a 5% minoxidil and finasteride topical solution enriched with redensyl and procapil for hair regrowth. They mentioned inconsistency in using the treatment and initially starting it without consulting a dermatologist.
The user is considering adding liposomal dutasteride to their hair loss treatment, which currently includes topical finasteride and minoxidil. They are exploring different concentrations and application frequencies to enhance hair retention and are also planning to continue using Rogaine.
A user received a topical finasteride solution from a pharmacy, which likely dissolved finasteride tablets instead of using pure finasteride powder, resulting in sediment. The user expressed dissatisfaction, expecting pure powder, and discussed the pros and cons of DIY solutions and the use of minoxidil with finasteride.
Pyrilutamide shows minimal systemic absorption with low plasma levels and no accumulation, suggesting it's unlikely to cause systemic side effects. However, full results are not yet published in scientific journals.
A user was prescribed Alpicort E, which contains Estradiol Benzoate, Prednisone, and Salicylic Acid, for hair loss and is seeking others' experiences due to concerns about potential side effects.
Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.
PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.
Kintor Pharma successfully dosed the first patient in a Phase II trial for KX-826 for acne vulgaris. Users are more interested in results for male pattern baldness (MPB).
A 24-year-old male has been using finasteride for 7 months and noticed thinning hair, especially when wet, and is concerned about the effectiveness of the treatment. Suggestions include continuing finasteride, considering minoxidil, and possibly trying micro-needling.
KX826 is considered a legitimate option for those who cannot use finasteride or dutasteride, but many users report it as ineffective compared to RU58841. RU58841 is favored by some due to anecdotal evidence of effectiveness, despite the lack of published clinical data.
The user reported initial hair regrowth and improved hair quality after starting finasteride, but noticed a return of hair loss after about a year. They also experienced side effects like erectile dysfunction and watery semen, which later improved.
The user experienced good hair growth results using a combination of finasteride, minoxidil, and a topical formulation, but faced temporary numbness as a side effect. They manage this by microdosing oral finasteride and minoxidil and using the topical formulation sparingly.
Microneedling may enhance hair loss treatment by increasing the effectiveness of topical minoxidil, especially for those lacking the necessary enzyme to activate it. It might also work by triggering growth factors and improving topical absorption.
The user shared two-month results using a topical spray with 0.3% finasteride, 7% minoxidil, 2.2% ketoconazole, and 0.2% biotin, showing improvement in hair loss. The user also mentioned using hair fibers previously and dermastamping inconsistently.
Someone looking for solutions to their hair loss, who has tried and failed to tolerate anti-androgen treatments such as finasteride, CB-03-01, RU58841, and Eucapil. The user is seeking advice and understanding of their extreme sensitivity to these treatments.
Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.